Evaluation of combination treatment with a BRAF inhibitor (BMS-908662) and CTLA-4 monoclonal antibody in preclinical models.

e13055 Background: The antitumor activity and immunomodulatory effect of an ipilimumab homolog antibody in combination with BMS-908662, a selective RAF inhibitor, were assessed in preclinical model...